Funa

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Funa

Quick Facts

Property Description
Active Ingredient Fluconazole (INN)
Form Primarily Oral Tablet/Capsule
Pharmacological Class Triazole Antifungal Agent
Common Purpose Systemic Fungal Infection Treatment
Origin Synthetic (Man-made)

What Type of Medicine is Funa and What is its Purpose?

Funa is a brand name for the generic medicine fluconazole, which is a powerful, synthetic antifungal drug belonging to the triazole class. This medication is recognized for its essential role in global health and is included on the Model List of Essential Medicines due to its importance in public health. Funa's primary purpose is to address infections caused by various fungal organisms, such as yeasts and molds. Fluconazole is an established first-line therapy for many systemic fungal diseases and remains effective in clearing widespread fungal infections.

Funa's Form, Composition, and Foundational Principle

Funa is primarily administered via the oral route, commonly available as a prescription-only tablet or capsule, and is a single-ingredient product. The only active substance is fluconazole. Being an oral medication, Funa is absorbed into the bloodstream, making it a systemic treatment capable of reaching infection sites deep within the body, such as internal organs or blood, unlike antifungal creams that treat only the surface.

The medication works by targeting the fungal cell itself. It actively inhibits the fungus's ability to produce ergosterol, a vital component needed to build its protective outer wall. This targeted mechanism allows Funa to effectively stop the infection from growing and helps the body eliminate the fungal cells. This systemic approach is essential for a typical use scenario like treating recurrent yeast infections or managing widespread fungal issues that require internal intervention.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Funa?

Funa: Possible Side Effects and Safety Information

This information details the potential side effects and safety restrictions of Funa as documented in official government health authority regulatory labels (such as FDA and EMA).

Adverse Reaction Scope

Official regulatory documents classify documented adverse reactions (side effects) using a standardized frequency framework, ranging from Very Common (ge 1/10) to Very Rare (< 1/10,000). These effects are also categorized by the body system affected, known as System Organ Classes (SOCs), which may include, for example, Gastrointestinal disorders, Nervous system disorders, and Blood and lymphatic system disorders.

Serious Adverse Reactions

The most significant potential risks associated with Funa are outlined in the official documentation as Serious Adverse Reactions or Warnings. These are typically low-frequency events that require immediate medical attention or have severe, potentially life-threatening outcomes.

Safety Restrictions and Warnings

Official regulatory sources define specific Contraindications—conditions or patient groups for which the use of Funa is strictly prohibited due to unacceptable risk. Furthermore, specific Precautions and Warnings are documented, indicating situations that require heightened monitoring or caution, such as use in patients with pre-existing hepatic or renal impairment.

Population-Specific Safety

Where documented in the regulatory label, specific safety considerations apply to certain groups. This includes formal statements regarding the documented risks of using Funa during pregnancy or lactation, and distinct safety profiles or warnings noted for the pediatric or geriatric populations.

Summary of the Official Safety Profile

The regulatory safety information for Funa establishes a clear, evidence-based risk hierarchy. This structure ensures that potential side effects, from expected, common events to rare, serious risks, are formally documented and communicated. The official label also provides the mandatory limitations and restrictions on the medicine's use to manage known safety concerns.

Overdose and Emergency Response

Overdose and When to Seek Help

Funa overdose is a life-threatening medical emergency requiring immediate attention. Clinical manifestations generally involve severe central nervous system (CNS) and respiratory depression. A toxic amount of the drug overwhelms the body's normal functions, which can be fatal if not managed promptly.

Signs of a potential overdose are consistent with severe depressant effects and may include:

Physiological System Documented Manifestations
Respiratory Slowed, shallow, or absent breathing (respiratory depression)
Circulatory Slowed heart rate, low blood pressure, pale or clammy skin
Neurological Confusion, extreme drowsiness, loss of consciousness, or coma
Ocular Pinpoint (constricted) pupils

Overdose risk factors include taking the drug at higher-than-prescribed doses, using it with other depressant substances such as alcohol or other medications, or using unapproved or counterfeit versions. Respiratory failure is the most dangerous consequence due to lack of oxygen reaching the brain, which can lead to permanent damage.

If any signs of overdose are observed, immediately contact emergency medical services. The administration of an opioid antagonist, if available, followed by continuous monitoring and supportive care is critical until professional help arrives.

Therapeutic Uses of Funa

Funa is relevant in therapeutic contexts where systemic or severe fungal infections require management. It is commonly used to help with a wide range of conditions, from deep-seated organ and bloodstream infections to recurring mucosal issues.

Funa is applied in addressing conditions marked by increased physiological stress, such as fungal infections in the blood (candidemia) or the lining of the brain (cryptococcal meningitis). It is also relevant for managing symptoms associated with recurrent or episodic manifestations of candidiasis, such as vaginal candidiasis or infections of the esophagus or throat.

Quick Fact: Support for Symptoms of Localized Irritation and Systemic Fever

The medication provides supportive relief when symptoms interfere with routine activities. “It contributes to improved comfort during symptomatic periods by easing distress,” and may assist with maintaining functional stability in contexts involving heightened systemic burden or recurrent flare-ups. Funa is also considered relevant when short-term symptomatic assistance is needed to prevent infection in high-risk patients, supporting general well-being during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview of Fluconazole

Eligibility and Restrictions for Use

The official regulatory profile for Funa (fluconazole) defines patient eligibility based on specific contraindications, physiological status, and age.

Eligibility Scope

Classification Eligibility Rule Summary (Official Labeling)
Contraindicated Populations Patients with known hypersensitivity to fluconazole, related azoles, or any excipients must not use Funa. Use is also prohibited when co-administered with specific drugs that prolong the QTc interval and are metabolized by the CYP3A4 enzyme, such as terfenadine or pimozide.
Age-Related Eligibility Funa is established for use in adults and children, including term newborn infants. However, safety and efficacy for treating genital candidiasis are not established in the pediatric population. Elderly patients are eligible, with dosage based on renal function, not age alone.
Condition-Specific Restrictions Patients with impaired renal function require restricted use with a dosage adjustment for multi-dose regimens (Creatinine Clearance le 50 mL/min). Those with hepatic impairment or specific cardiac conditions (e.g., heart rhythm problems) must use Funa with caution. Formulation-specific comorbidities, such as certain rare hereditary sugar intolerances, prohibit the use of the respective tablet or oral suspension forms.
Reproductive Status Use during pregnancy is generally not recommended, and is contraindicated for prolonged, high-dose (ge 400 mg/day) regimens, except for potentially life-threatening infections. Breastfeeding is permitted after a single low-dose regimen (e.g., 150 mg) but not recommended after repeated or high-dose use.

Eligibility Classification

Official regulatory documents classify eligibility into several severities: Contraindicated (absolute prohibition), Not Recommended (avoidance unless clearly necessary), and Conditional Use (requiring dose adjustment or caution). This structure dictates who must not use the medicine and who may use it only with strict, documented considerations.

What should I know about interactions with other medicines?

Funa can interact with a wide range of prescription and over-the-counter (OTC) medications, herbal products, and certain foods, which can potentially change how Funa or the other product works. These interactions may increase the concentration of Funa or the co-administered drug in the blood, leading to an elevated risk of side effects, or decrease the drug's effectiveness.

Key Drug-Drug Interactions

Particular caution is required with medicines that are metabolized by or affect cytochrome P450 enzymes, especially CYP3A4 and CYP2C9. These may include, but are not limited to:

  • Anticoagulants (Blood Thinners): Co-administration may increase the risk of bleeding. Close monitoring and dose adjustment may be necessary.
  • Statins: Taking Funa with certain cholesterol-lowering drugs (e.g., simvastatin or lovastatin) can significantly increase their levels, raising the risk of serious muscle issues.
  • Oral Hypoglycemics: The combination may increase the blood-sugar-lowering effect, requiring careful glucose monitoring.
  • Drugs that Prolong the QT Interval: This combination can increase the risk of a serious, potentially fatal heart rhythm abnormality. These combinations are generally avoided.
Interaction Type Examples of Affected Products
Drug-Food Grapefruit juice may increase Funa's levels.
Drug-Alcohol Concurrent use may increase side effects like dizziness and liver stress.

Always provide your healthcare provider with a complete, up-to-date list of all medicines, vitamins, and herbal supplements you are currently taking before starting Funa.

Mechanism of Action

Ontology of Action: How Funa Works

Funa (fluconazole) operates exclusively at the cellular level of the fungal organism, engaging a highly specific biochemical pathway that leads to structural and functional failure. This mechanism contributes to the systemic antifungal action and is defined by two key domains: enzyme inhibition and structural destabilization.


Targeted Inhibition of Fungal Ergosterol Synthesis

This domain covers the initial molecular interaction where Funa selectively binds to and inhibits the fungal enzyme Lanosterol 14-alpha demethylase (CYP51). This enzyme is a crucial component in the ergosterol biosynthesis pathway. The drug's molecule coordinates and binds to the heme iron within the enzyme's active site, effectively halting its function. This mechanism directly blocks the synthesis of ergosterol, which is essential for fungal structure.


Disruption of Fungal Cellular Permeability and Homeostasis

The resulting physiological consequence of enzyme inhibition is a failure in fungal cell structure. By depleting the essential ergosterol and causing the buildup of toxic intermediate sterols, the drug compromises the cell membrane's integrity, leading to increased permeability and the resultant inhibition of fungal proliferation and maintenance functions. This specialized mechanism contributes to the systemic antifungal action by causing the structural and functional failure of the pathogen.

Dosage and Administration Information

How Funa (Fluconazole) Is Used

The usage of Funa is defined by official administration protocols that establish the required route, dosing schedule, and duration based on the condition being addressed. As a systemic antifungal, it is approved for administration through two main routes: oral (capsules, tablets, or suspension) and intravenous (IV) infusion. The daily dose is consistent regardless of the route used.

Standard Dosing and Frequency

Most multi-day treatments initiate with a loading dose on the first day, which is typically double the subsequent maintenance dose, designed to quickly establish therapeutic levels. This is followed by a standard once-daily maintenance schedule. For acute conditions like vaginal candidiasis, the standard protocol is a single oral dose of 150 mg. For recurrent or maintenance therapy, Funa is often used intermittently, such as a single dose administered once per week for several months. Funa may be taken with or without food.

Administration and Adjustments

Official instructions require specific procedures for administration. For oral suspension, the liquid must be shaken well before use. The IV form must be administered slowly as an infusion, at a rate that generally does not exceed 10 mL per minute. Crucially, dose adjustments are mandatory for certain populations. Patients with renal impairment (reduced kidney function) typically require a 50% reduction in the standard daily maintenance dose after the initial loading dose, while pediatric dosing is calculated based on body weight (mg/kg).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Funa

Evidence for Use in Severe and Systemic Fungal Infections

Research has explored Funa in contexts involving severe internal fungal infections, such as those that affect the bloodstream (candidemia) or the central nervous system (cryptococcal meningitis). Studies in this area primarily include large-scale retrospective cohort analyses and systematic reviews conducted on hospitalized patients. These studies monitored fungal pathogen measurements and patient status over defined time intervals.

Studies monitored patient status and reported findings related to patients who were observed receiving Funa. Comparative studies examined the patterns observed when Funa was studied for susceptible infections versus other antifungal agents, and studies monitored patient status at 60 days, and the findings were compared. Despite the existing research base, uncertainty remains regarding the predictive relationship between drug exposure in the body and a patient's clinical outcome.

Research on Recurring Fungal Conditions

Research was studied for conditions characterized by fluctuating or episodic manifestations, such as recurrent vulvovaginal candidiasis (RVVC). Controlled trials examined outcomes related to physical discomfort and the time until recurrence. The findings describe patterns where a higher proportion of patients were observed in a non-symptomatic status during the active maintenance phase compared to those receiving the inactive substance.

Long-term effects are not fully established regarding permanent resolution. Studies consistently reported that recurrence was often observed following the discontinuation of the maintenance regimen. The findings describe group patterns, not personal outcomes; the existing research does not determine whether an individual will respond similarly with a permanent resolution.

Studies on Preventive Use (Prophylaxis) in High-Risk Groups

Funa was evaluated in studies focused on the prevention of infection (prophylaxis) in specific vulnerable groups, such as very low birth weight preterm infants and bone marrow transplant recipients. Studies describe patterns where a lower incidence of invasive fungal disease was observed in some studies during the active treatment period for prophylaxis groups. However, studies also report patterns where some fungal species observed were found to be less susceptible to Funa, and research on patient status showed mixed findings across different trials in some high-risk groups.

Key Studies & References

  1. WHO Model List of Essential Medicines - Fluconazole
  2. Fluconazole (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Funa (FAQ)


Q: Does Funa work right away, or does it take time to notice effects?

A: Official information indicates that the standard regimen often includes a loading dose on the first day. This method is used to help the medicine reach concentrations close to steady-state (a consistent level in the body) by the second day of treatment. The time until a patient notices effects can vary.


Q: Do the side effects of Funa usually go away over time?

A: Official information suggests these effects may be temporary, often lasting a few days or weeks as part of the body's adjustment period. Common side effects like headache and nausea are generally described as resolving on their own.


Q: What is the difference between Funa and similar drugs with a different name?

A: Funa is chemically classified as a synthetic triazole antifungal agent, which defines its structure and mechanism of action for treating systemic infections. This classification helps distinguish it from other types of antifungal medications that belong to different chemical classes.


Q: Does Funa interact with birth control pills?

A: Official prescribing information states that Funa may increase the blood level of certain oral contraceptives. This potential drug-drug interaction is documented and is a topic for discussion with a healthcare provider.


Q: Is Funa gluten-free?

A: Regulatory descriptions of the product list all inactive ingredients (excipients). The necessity of checking for excipients, such as gluten, depends on the patient’s needs and the specific product labeling.


Q: What happens if I forget to take Funa?

A: For multi-day treatment, regulatory instructions generally state that if a dose is missed, it should be taken as soon as it is remembered. However, if it is close to the next scheduled dose, the missed dose should typically be skipped and the regular schedule resumed. Regulatory guidelines advise against taking a double dose to compensate for the missed one.


Q: How is Funa different from supplements or herbal remedies for the same condition?

A: Funa is a synthetic triazole antifungal medicine classified as a prescription drug with a defined, targeted, and studied systemic mechanism of action. Supplements and herbal remedies are not subject to the same regulatory requirements or classifications as prescription medications.


Q: Is Funa generally well tolerated?

A: Official information lists common side effects, such as headache and nausea, that are typically mild. Serious adverse reactions are outlined in the official warnings but are reported to be rare.


Q: Are there any common vitamins or mineral supplements that interact with Funa?

A: Funa primarily works by inhibiting certain liver enzymes. Regulatory resources indicate no known Major, Moderate, or Minor interactions with common vitamins like B12, C, or D. As with any substance, full disclosure of all medications and supplements to a healthcare provider is generally necessary.


Q: Does Funa affect blood sugar levels?

A: The official label describes an interaction where Funa can significantly increase the concentration and effect of certain oral hypoglycemic agents (drugs used to lower blood sugar). This increase can lead to a risk of low blood sugar (hypoglycemia).


Q: How long does Funa stay in your system?

A: According to official product information, the drug has a terminal plasma elimination half-life of approximately 30 hours in healthy volunteers. This means it takes about 30 hours for half of the drug to be eliminated from the body.


Q: Is Funa safe for older people?

A: Eligibility for older patients is established according to official regulatory documents. However, the dosage is determined by their renal function (kidney function). The use in older patients requires careful consideration of renal function.


Q: Does Funa affect sleep patterns?

A: Regulatory documents list somnolence (drowsiness) as an Uncommon side effect reported in the Nervous System disorders category (0.1% to 1%).


Q: Is it normal to feel tired when first starting Funa?

A: The official regulatory side effect data includes fatigue and unusual tiredness or weakness as effects that have been reported. These are listed in the 'Uncommon' or 'Frequency not known' categories.


Q: Is it true that Funa has a risk of dependence?

A: Official regulatory safety documentation for Funa does not list a risk of dependence or abuse potential.


Q: Does Funa cause dry mouth?

A: Official regulatory information lists dry mouth as an Uncommon side effect (0.1% to 1%) reported in the Gastrointestinal System Organ Class.


Q: Are there any known interactions between Funa and common vaccines?

A: Current drug interaction checkers, which rely on regulatory data, have not found any known drug interactions between Funa and certain common vaccines, such as the SARS-CoV-2 Ad26 vaccine.


Q: Does Funa show up on a standard drug test?

A: Funa is not a controlled substance and is not typically included in or detected by standard drug screens. However, specialized laboratory tests are available to measure its concentration in the blood for therapeutic monitoring purposes.


Q: What are the key ingredients in Funa besides the main active component?

A: Beyond the active ingredient, fluconazole, the official label lists various inactive ingredients (excipients). For instance, the capsule forms often contain lactose, and the powder for oral suspension typically lists sucrose.


Q: Is Funa intended for short-term or long-term use?

A: Funa is approved and used for both short-term, single-dose treatments for acute conditions, as well as for long-term use in maintenance therapy or to prevent recurrence in specific high-risk patient groups.


Q: Is Funa linked to mood changes or anxiety?

A: The official safety profile has reported mood changes in the post-marketing experience with an unknown frequency. Mental depression is also listed in post-marketing reports related to adrenal gland problems.


Q: Why do doctors check my blood work when I start Funa?

A: Official warnings and precautions state the medication is linked to potential issues like liver problems (hepatotoxicity). Blood work may be conducted by the prescriber to monitor overall patient status and help optimize dosing.


Q: Why do some people report feeling dizzy on Funa?

A: Dizziness is listed in official regulatory information as an Uncommon side effect (0.1% to 1%) reported in the Nervous System disorders. It can also be a symptom of a rare, serious heart rhythm change mentioned in official warnings.


Q: How long after stopping Funa do I need to worry about interactions?

A: Funa has a long elimination half-life, approximately 30 hours, meaning it stays in the body for an extended period. The clearance time means that potential interactions may be considered during this period.

How should Funa be stored and disposed of?

How to Store and Dispose of Funa?

The storage and disposal instructions for Funa (fluconazole) are specified in official regulatory documents to maintain drug quality and ensure public safety.

Funa tablets and capsules must be stored at room temperature, generally not exceeding 30 C (86 F), and must be protected from freezing, excessive heat, light, and moisture. The medicine must remain in its original container, which should be kept tightly closed.

Crucially, Funa must be stored out of the sight and reach of children and pets. If the product is the oral suspension form, any unused portion must be discarded after 14 days of reconstitution.

To dispose of unused or expired Funa, utilize drug take-back programs or a specified household disposal procedure. The medicine must not be thrown into wastewater or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Funa found in:

A-Z Index: